PHARMING GROUP NV (PHARM.AS)
NL0010391025 - Common Stock
Taking everything into account, PHARM scores 3 out of 10 in our fundamental rating. PHARM was compared to 77 industry peers in the Biotechnology industry. PHARM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHARM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHARM had negative earnings in the past year.
In the past year PHARM has reported a negative cash flow from operations.
Of the past 5 years PHARM 4 years were profitable.
Of the past 5 years PHARM 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.28%, PHARM is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
The Return On Equity of PHARM (-4.82%) is better than 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.28% | ||
| ROE | -4.82% | ||
| ROIC | N/A |
ROA(3y)1.65%
ROA(5y)5.8%
ROE(3y)3.38%
ROE(5y)12.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 89.72%, PHARM belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
PHARM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y1.43%
2. Health
2.1 Basic Checks
PHARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHARM has been increased compared to 1 year ago.
Compared to 5 years ago, PHARM has more shares outstanding
PHARM has a better debt/assets ratio than last year.
2.2 Solvency
PHARM has an Altman-Z score of 0.31. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PHARM (0.31) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.76 indicates that PHARM is somewhat dependend on debt financing.
The Debt to Equity ratio of PHARM (0.76) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.76 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.31 |
ROIC/WACCN/A
WACC4.61%
2.3 Liquidity
PHARM has a Current Ratio of 4.06. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHARM (4.06) is better than 77.78% of its industry peers.
A Quick Ratio of 3.33 indicates that PHARM has no problem at all paying its short term obligations.
The Quick ratio of PHARM (3.33) is better than 65.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.33 |
3. Growth
3.1 Past
The earnings per share for PHARM have decreased strongly by -900.00% in the last year.
PHARM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.30%.
PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.35% yearly.
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q80%
Revenue 1Y (TTM)19.3%
Revenue growth 3Y4.96%
Revenue growth 5Y11.35%
Revenue growth Q2Q48.69%
3.2 Future
The Earnings Per Share is expected to grow by 79.89% on average over the next years. This is a very strong growth
PHARM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.00% yearly.
EPS Next Y153.11%
EPS Next 2Y95.82%
EPS Next 3Y82.92%
EPS Next 5Y79.89%
Revenue Next Year18.67%
Revenue Next 2Y16.65%
Revenue Next 3Y16%
Revenue Next 5Y12%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHARM. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 110.79, which means the current valuation is very expensive for PHARM.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHARM indicates a somewhat cheap valuation: PHARM is cheaper than 70.83% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.63. PHARM is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 110.79 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHARM's earnings are expected to grow with 82.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y95.82%
EPS Next 3Y82.92%
5. Dividend
5.1 Amount
No dividends for PHARM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PHARMING GROUP NV
AMS:PHARM (4/25/2024, 7:00:00 PM)
0.881
-0.02 (-2.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap59.33M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 110.79 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.28% | ||
| ROE | -4.82% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.76 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y153.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.3%
Revenue growth 3Y4.96%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y